de Groot-Kruseman H A, Baan C C, Loonen E H, Mol W M, Niesters H G, Maat A P, Balk A H, Weimar W
Department of Internal Medicine, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands.
J Heart Lung Transplant. 2001 May;20(5):503-10. doi: 10.1016/s1053-2498(00)00325-9.
Brain-death, ischemia and reperfusion damage have been implicated as initial factors that lead to a cascade of immunologic events that result in allograft rejection in experimental animals. Cytokines are thought to play a central role in this process. Therefore, we evaluated intragraft cytokine mRNA expression at an early stage after clinical heart transplantation and related these data to ischemia, immunosuppression, and rejection.
We sampled endomyocardial biopsies at 30 minutes (EMB 0) and at 1 week (EMB 1) after transplantation from 20 cardiac allograft recipients. Intragraft monocyte chemoattractant protein (MCP-1) and basic fibroblast growth factor (bFGF) mRNA expression levels were quantitatively measured using competitive template Reverse-transcriptase polymerase chain reaction (RT-PCR).
We measured significantly lower MCP-1 and bFGF mRNA expression levels in EMB 1 compared with EMB 0 (MCP-1, p = 0.006; bFGF, p = 0.019). We found no direct correlation between the cytokine mRNA expression levels in EMB 0 or EMB 1 and ischemic times, induction therapy, or cyclosporine whole-blood trough levels. Patients with a high incidence of acute rejection episodes (>2 in the first year) had higher bFGF mRNA expression levels (p = 0.009) and comparable MCP-1 mRNA expression levels (p = 0.378) at 1 week, compared with patients with a lower rejection incidence. The MCP-1 and bFGF mRNA expression levels in the first week were not associated with the development of graft vascular disease in the first year post-transplant.
We found a significant decrease of intragraft MCP-1 and bFGF mRNA expression levels in the first post-operative week. Patients with a high incidence of acute rejection had higher bFGF mRNA expression levels in their first week biopsy. Therefore, we conclude that patients who fail to down-regulate their bFGF mRNA expression early after transplantation are at higher risk for acute rejection.
脑死亡、缺血及再灌注损伤被认为是导致一系列免疫事件的初始因素,这些免疫事件会导致实验动物发生同种异体移植排斥反应。细胞因子被认为在这一过程中起核心作用。因此,我们评估了临床心脏移植术后早期移植物内细胞因子mRNA的表达情况,并将这些数据与缺血、免疫抑制及排斥反应相关联。
我们从20名心脏同种异体移植受者中,在移植后30分钟(心肌内膜活检0)和1周(心肌内膜活检1)采集心肌内膜活检样本。使用竞争性模板逆转录聚合酶链反应(RT-PCR)定量测量移植物内单核细胞趋化蛋白(MCP-1)和碱性成纤维细胞生长因子(bFGF)mRNA的表达水平。
与心肌内膜活检0相比,我们测得心肌内膜活检1中的MCP-1和bFGF mRNA表达水平显著降低(MCP-1,p = 0.006;bFGF,p = 0.019)。我们发现心肌内膜活检0或心肌内膜活检1中的细胞因子mRNA表达水平与缺血时间、诱导治疗或环孢素全血谷浓度之间无直接相关性。与急性排斥反应发生率较低的患者相比,急性排斥反应发作发生率较高(第一年>2次)的患者在1周时bFGF mRNA表达水平较高(p = 0.009),MCP-1 mRNA表达水平相当(p = 0.378)。第一周的MCP-1和bFGF mRNA表达水平与移植后第一年移植物血管疾病的发生无关。
我们发现在术后第一周移植物内MCP-1和bFGF mRNA表达水平显著降低。急性排斥反应发生率高的患者在第一周活检时bFGF mRNA表达水平较高。因此,我们得出结论,移植后未能早期下调bFGF mRNA表达的患者发生急性排斥反应的风险更高。